Dagmar Arnold, MD
Endocrinology, Diabetes & Metabolism · Olney, MDNPI 1881649432
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,561 of the $8,873 with a category attached, or 85.2%. 29 manufacturers reported payments, led by Lilly USA, LLC at 24.2% of the total.
Across 303 payments — averaging $29.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$1K
- AstraZeneca$802
- Sanofi-aventis U.S. LLC$792
- AbbVie$769
- Amneal Pharmaceuticals LLC$706
- plus $2K from 23 others
What the payments were for
- Consulting fees$1752%
- Speaking & faculty fees$1,10512%
- Food & beverage$7,56185%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 92 | $2,144 |
| Novo Nordisk | 42 | $1,406 |
| AstraZeneca | 25 | $802 |
| Sanofi-aventis U.S. LLC | 6 | $792 |
| AbbVie | 36 | $769 |
| Amneal Pharmaceuticals LLC | 35 | $706 |
| Sanofi US Services Inc. | 1 | $350 |
| Amgen | 2 | $300 |
| Boehringer Ingelheim | 15 | $293 |
| Bayer | 5 | $215 |
| Corcept Therapeutics | 3 | $161 |
| Dexcom, Inc. | 2 | $146 |
| BETA Bionics, Inc. | 1 | $119 |
| Xeris Pharmaceuticals, Inc. | 6 | $110 |
| Amarin Pharma, Inc. | 7 | $93 |
| Abbott | 5 | $93 |
| Merck | 5 | $72 |
| Radius Health, Inc. | 3 | $56 |
| Cequr Corporation | 1 | $43 |
| IBSA Pharma Inc. | 2 | $39 |
| Embecta Corp. | 1 | $26 |
| Exact Sciences | 1 | $25 |
| Johnson & Johnson | 1 | $20 |
| Madrigal Pharmaceuticals | 1 | $19 |
| Pfizer | 1 | $17 |
| Medtronic | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Mannkind Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$700
- Ozempic$369
- FARXIGA$369
- iLet Bionic Pancreas$357
- TOUJEO$350
- Wegovy$225
- Synthroid$220
- Prolia$175
- Kerendia$146
- Repatha$125
- iLet Insulin Infusion Kit Inset$119
- iLet Insulin Infusion Kit Contact Detach$119
- DEXCOM G7 GSS (161)$118
- DEXCOM STELO GLUCOSE BIOSENSOR$118
- Korlym$116
- MOUNJARO$111
- Xultophy 100/3.6$106
How this compares
$8,873 in reported general payments places this provider in the 85th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 75 | $99,994 |
| TrulicityDulaglutide | 51 | $93,206 |
| JardianceEmpagliflozin | 60 | $82,265 |
| OzempicSemaglutide | 40 | $61,848 |
| GlyxambiEmpagliflozin/Linagliptin | 45 | $55,828 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $41,139 |
| ProliaDenosumab | 18 | $31,099 |
| FarxigaDapagliflozin Propanediol | 19 | $24,307 |
| TradjentaLinagliptin | 16 | $21,847 |
| JanuviaSitagliptin Phosphate | 14 | $15,108 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $5,283 |
| SynthroidLevothyroxine Sodium | 52 | $4,237 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $3,372 |
| Nateglinide | 49 | $3,093 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 25 | $2,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $2,144 | $193,200126 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $293 | $159,940121 claims |
| Novo NordiskOzempic | $1,406 | $61,84840 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $792 | $41,13925 claims |
| AmgenProlia | $300 | $31,09918 claims |
| AstraZenecaFarxiga | $802 | $24,30719 claims |
| MerckJanuvia | $72 | $15,10814 claims |
| AbbVieSynthroid | $769 | $4,23752 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $706 | $2,075180 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Olney
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
- Helena RodbardRockville$468K
- Roy PhillipsBel Air$208K
- Eyob MakonnenAnnapolis$205K
- Jawaad KhokharGlen Burnie$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.